Working… Menu
Trial record 5 of 45 for:    Han weidong

Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas (CIK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01828008
Recruitment Status : Unknown
Verified January 2013 by Han weidong, Chinese PLA General Hospital.
Recruitment status was:  Not yet recruiting
First Posted : April 10, 2013
Last Update Posted : April 10, 2013
Information provided by (Responsible Party):
Han weidong, Chinese PLA General Hospital

Brief Summary:
To study the safety and efficacy of CD20 antibody usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.

Condition or disease

Detailed Description:
Autologous CIK transfusion within 3 days post CD20 antibody treatment.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 20 participants
Observational Model: Case-Control
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Study Start Date : April 2013
Estimated Primary Completion Date : May 2015
Estimated Study Completion Date : May 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Primary Outcome Measures :
  1. disease free survival [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
the patients with CD20-positive Lymphomas

Inclusion Criteria:

- diagnosed as B-cell lymphoma with CD20 positiveness, and need to therapy

Exclusion Criteria:

- to refuse the therapy and need not tolerate the therapy

Additional Information:

Layout table for additonal information
Responsible Party: Han weidong, combination of anti-CD20 with CIK for refractory lymphomas, Chinese PLA General Hospital Identifier: NCT01828008    
Other Study ID Numbers: BT-004
First Posted: April 10, 2013    Key Record Dates
Last Update Posted: April 10, 2013
Last Verified: January 2013
Keywords provided by Han weidong, Chinese PLA General Hospital:
cytokine induced killer cell
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases